In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

ETFE-Coated Syringe Plunger Machinability with Vented Insertion
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

The Art of CCIT: Deterministic Method Selection
Webinars, Pharmaceutical, Market Insights, Product Solutions

Vial Stopper Compatibility: Criteria and Testing Methods
Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Derisking the Development of Sensitive Injectables
Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions